Catalyst Pharma (CPRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein...
Should you buy catalyst Pharma (cprx – research report)?
Catalyst Pharma ( CPRX – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $26.00 price target.
Should you buy catalyst Pharma (Firdapse) stock?
Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $26.00 price target. Andrew Fein has given his Buy rating due to a combination of factors centering around Catalyst Pharma’s recent developments with their drug, Firdapse.
